It has been more than three decades since the first description of a cystoscopically placed indwelling endoluminal splint by Zimskind and colleagues in 1967. Ureteral stent placement is now considered a routine and indispensable urologic tool (Chew et al., 2004). However, the side effects and patient morbidity associated with ureteral stents have been identified as a potential health problem (Dyer et al., 2002). The great variety of complications range from the commonly experienced “stent syndrome” to the medicolegal dilemma of the forgotten stent. Only recently researchers have directed their efforts for the assessment of stent-related symptoms and the evaluation of their impact on patients’ daily life. Although most efforts have been aimed toward improving stent materials and design, it was hypothesized that a selective alpha1-blocker, such as tamsulosin, might influence the stent-related symptoms, because the latter mimic the lower urinary tract symptoms due to benign prostatic hyperplasia.